Barinthus Biotherapeutics plc
Script error: No such module "Draft topics".
Script error: No such module "AfC topic".
| Public | |
| Traded as | NASDAQ: BRNS |
| ISIN | 🆔 |
| Industry | Immunotherapy Biotechnology |
| Founded 📆 | 2016 |
| Founder 👔 | |
| Headquarters 🏙️ | , , |
Area served 🗺️ | |
| Members | |
Number of employees | |
| 🌐 Website | barinthusbio |
| 📇 Address | |
| 📞 telephone | |
Barinthus Biotherapeutics plc is a clinical-stage biotechnology company developing immunotherapies for chronic infectious diseases, autoimmunity and cancers such as hepatitis B, HPV, celiac disease and prostate cancer. In November 2023, the company announced that it had rebranded from Vaccitech to Barinthus Biotherapeutics plc.[1]
Technology[edit]
The company's platforms include Chimpanzee Adenovirus Oxford (ChAdOx) and Modified Vaccinia Ankara (MVA), two viral vectors which safely mimic viral infection in human cells and elicit antibody and T cell responses to pathogens and tumours, as well as two SNAP synthetic platforms, SNAP-TI (SNAP-Tolerance Immunotherapy) and SNAP-CI (SNAP-Cancer Immunotherapy), previously referred to collectively as SNAPvaxTM.
History[edit]
The company was founded in 2016 as Vaccitech, a University spin-off by Sarah Gilbert and Adrian V. S. Hill at The Jenner Institute, University of Oxford.[2][3][4]
Barinthus Bio has been financed and supported by M&G Catalyst, Google Ventures (GV), Fosun International, Tencent, Huawei, Sequoia Capital, GeneMatrix, Liontrust Asset Management, Korea Investment Partners and Oxford Sciences Innovation (OSI).[5][6] [7]
In early 2020, Barinthus Bio, then known as Vaccitech, and the University of Oxford co-invented a vaccine for COVID-19 using the ChAdOx platform.[8]
COVID-19 vaccine[edit]
In July 2020, it was reported that people in Brazil, South Africa and the US had been recruited to populate the vaccine trials.[9]
In July 2020, Barinthus Bio scientists reported in The Lancet a "single-blind, randomised controlled trial in five trial sites in the UK of a chimpanzee adenovirus-vectored vaccine (ChAdOx1 nCoV-19) expressing the SARS-CoV-2 spike protein." Several subjects needed prophylactic paracetamol to minimize their adverse reactions.
Listing on NASDAQ[edit]
Barinthus Bio, then known as Vaccitech, held an initial public offering of shares in 2021, listing on NASDAQ on 30 April 2021 under the symbol VACC, now BRNS.[10]
References[edit]
- ↑ "Vaccitech rebrands as Barinthus Biotherapeutics". thepharmaletter.com. Retrieved 28 November 2023.
- ↑ Anon (2019). "Vaccitech Ltd". bloomberg.com. Bloomberg News.
- ↑ Anon (2016). "Universal flu vaccine under development by Oxford spinout Vaccitech". ox.ac.uk. University of Oxford.
- ↑ Anon (2019). "Vaccitech secures £20m Series A with GV, OSI and Sequoia China". innovation.ox.ac.uk. Oxford University Innovation.
- ↑ Anon (2019). "About Vaccitech". vaccitech.co.uk. Vaccitech Limited.
- ↑ "Inside the Chinese companies developing a Covid-19 vaccine". The Week. 3 September 2020.
- ↑ Anon (2021). "M&G leads $168 million Vaccitech financing". mandgplc.com. M&G plc.
- ↑ Boseley, Sarah (1 July 2020). "Oxford offers best hope for Covid-19 vaccine this year, MPs told". Guardian News & Media Limited.
- ↑ "Vaccitech prices shares at IPO". Reuters. 30 April 2021.
This article "Barinthus Biotherapeutics" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Barinthus Biotherapeutics. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
